How Bayer and Its Pipeline Drive the Strongest Pharmaceutical Growth in the Future

Jakarta, VIVA – At the Bayer Pharma Media Day 2026, Stefan Oelrich, Member of the Board of Management of Bayer AG and President of the Pharmaceuticals Division, elaborated on the sustainable focus on scientific and business priorities as the primary driver for the company’s growth targets towards 2030. “With an unwavering focus on strategic priorities and scientific rigour, we are beginning to see the results of the transformation strategy we are implementing to drive growth,” said Stefan in Berlin, quoted on Saturday, 11 April 2026. Thanks to the strongest pharmaceutical portfolio it has ever had, a multimodal pipeline, and an operations model increasingly supported by artificial intelligence (AI), Bayer is on the right track to return to mid-single-digit growth starting from 2027, as well as expanding margins from 2028 to reach 30% by 2030. Meanwhile, Christine Roth, Member of the Bayer Pharmaceuticals Leadership Team, stated that the company is determined to be first or best in its class, as patients deserve the best. “The bold decisions we have made in recent years, supported by a capable team, have proven to accelerate innovation and deliver real impact for patients and for Bayer,” said Christine. A rigorous strategy to revitalise the pipeline through innovative and differentiated assets is beginning to show its potential, reflected in record performance in 2025, three new product approvals, two indication expansions for growth drivers, and six positive Phase III clinical trial results. In 2026, Bayer targets several key milestones that further validate the impact-by-innovation strategy, including precision treatments in core areas of cardiovascular and oncology, regenerative cell and gene therapies, and molecular imaging. Small molecule drugs remain one of the most effective ways to deliver high-impact therapies because they are easily accessible, predictable, and scalable globally. The company is also developing oral therapies for cancer and immunology diseases that target disease drivers previously considered undruggable, enabled by chemoproteomic screening platforms. With three internally developed molecules now in clinical development, the focus is on realising this work into new drugs with transformative potential for patients.